Study Type
Interventional - Drug
ongoing
ANNEXa-1 is a randomized, multicenter, Phase 4 clinical trial of 440 patients designed to determine the efficacy and safety of andexanet compared to usual care in patients presenting with acute intracranial hemorrhage.
Study Design
Prospective open-label RCT
NO. of Countries
10
NO. of Sites
100
NO. of Participants
440
Study Period
2019 - 2022
Sponsor
Portola Pharmaceuticals
Stuart Connolly
Senior Scientist
Stuart Connolly
Senior Scientist
Stuart Connolly is a Professor of Medicine at McMaster University and a cardiac electrophysiologist at Hamilton Health Sciences. He became a faculty member at McMaster University in 1983 and was awarded a full professorship in 1994. He was also appointed as the inaugural holder of the Salim Yusuf Chair in Cardiology at McMaster University.
He has published more than 270 scientific articles in the field, and is currently a member of the editorial boards for a number of prominent cardiology journals, including Heart, the American Heart Journal and the Journal of Pacing and Electrophysiology. His main research interests are focused on the evaluation of treatments for heart rhythm disorders. His academic career has been largely devoted to the design and execution of controlled clinical trials in this area.
He holds a Masters degree from Fordham University, New York, and an MD from McGill University in Montreal. He received his specialist training in cardiology at the University of Toronto and at Stanford University.
Amanda Taylor
Associate Program Manager
Amanda Taylor
Associate Program Manager
Amanda Taylor is an Associate Program Manager who currently coordinates trials in stroke, and has experience conducting trials in acute coronary syndrome and arrhythmia. Amanda joined PHRI in 2007. She holds a Bachelor of Science Degree (Honours) in Neurobiology from Brock University.
Portola Pharmaceuticals, Inc.
completed
ANNEXa-4
Thrombosis
In patients receiving a factor Xa inhibitor who are experiencing an acute major bleed, the...
